Wikipedia -WSS

Wikipedia

author：entertainment 2025-08-31 16:36:18 - browse：1

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

WSS

The drug industry has found itself all alone in Washington

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

In his State of the Union, Biden takes clear aim at 'Big Pharma'

UnitedHealth, Optum discontinue NaviHealth name

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Is there really a nursing shortage in the U.S.?

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Supreme Court strikes down use of affirmative action

Amylyx ALS drug failure raises questions and concerns

The high cost of giving birth even with insurance

STAT Summit: The economic case for universal basic health care

Anesthesiologist group: stop taking Ozempic before surgery

STAT Readout: Friday, Oct. 20 biotech updates

How one medical school became remarkably diverse

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

Cassava Sciences’ Alzheimer’s clinical trials should be halted

UnitedHealth, Optum discontinue NaviHealth name

Results on Novartis prostate cancer therapy could expand its use

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Summit: The economic case for universal basic health care

hotspot

entertainment

entertainment

Wikipedia